GAMMA Investing LLC Acquires 579 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

GAMMA Investing LLC grew its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 26.2% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,791 shares of the biopharmaceutical company’s stock after buying an additional 579 shares during the quarter. GAMMA Investing LLC’s holdings in Catalyst Pharmaceuticals were worth $68,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Castlekeep Investment Advisors LLC acquired a new position in Catalyst Pharmaceuticals during the fourth quarter valued at approximately $37,494,000. Bank of America Corp DE grew its holdings in Catalyst Pharmaceuticals by 139.5% during the fourth quarter. Bank of America Corp DE now owns 1,568,791 shares of the biopharmaceutical company’s stock worth $32,741,000 after purchasing an additional 913,843 shares during the period. Arrowstreet Capital Limited Partnership boosted its holdings in shares of Catalyst Pharmaceuticals by 131.4% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 698,152 shares of the biopharmaceutical company’s stock worth $14,570,000 after buying an additional 396,506 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Catalyst Pharmaceuticals by 4.9% during the fourth quarter. Vanguard Group Inc. now owns 8,431,094 shares of the biopharmaceutical company’s stock worth $175,957,000 after buying an additional 390,116 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new position in Catalyst Pharmaceuticals during the 4th quarter worth $6,887,000. 79.22% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald upgraded Catalyst Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, June 5th. Six equities research analysts have rated the stock with a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $32.83.

Catalyst Pharmaceuticals Stock Performance

NASDAQ CPRX opened at $20.75 on Wednesday. Catalyst Pharmaceuticals, Inc. has a one year low of $15.19 and a one year high of $26.58. The company has a market capitalization of $2.53 billion, a price-to-earnings ratio of 13.22, a PEG ratio of 0.85 and a beta of 0.66. The stock has a 50-day moving average of $23.61 and a 200 day moving average of $22.89.

Insider Activity

In other news, insider Gary Ingenito sold 200,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 13th. The shares were sold at an average price of $23.68, for a total transaction of $4,736,000.00. Following the sale, the insider owned 68,873 shares of the company’s stock, valued at $1,630,912.64. This trade represents a 74.38% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Preethi Sundaram sold 2,324 shares of the business’s stock in a transaction on Tuesday, June 10th. The stock was sold at an average price of $26.41, for a total value of $61,376.84. Following the transaction, the insider directly owned 42,681 shares in the company, valued at $1,127,205.21. This trade represents a 5.16% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 247,924 shares of company stock valued at $5,879,369. Company insiders own 10.40% of the company’s stock.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.